Items tagged with Access
US: Big price increase for tuberculosis drug is rescinded (post)
A huge overnight price increase for an important tuberculosis drug has been rescinded after the company that acquired the drug gave it back to its previous owner under pressure, it was announced on Monday.
U.S. pressure on India's pro-health patent law threatens Sustainable Development Goals (post)
Asia Pacific Network of People living with HIV/ AIDS (APN+) and HEALTH GAP Call on India to stand strong and defend the pharmacy of the Developing World
Answer to costly pills: Stop TB Partnership's Global Drug Facility - the platform for TB medicines amidst recent US drug storm (post)
In contrast to the recent US cycloserine price increase, the Global Drug Facility slashed the price of cycloserine by 55% earlier this year compared to the previous year.
India: Medicine for drug-resistant TB patients to benefit 800 in Maharashtra (post)
PUNE, Sep 25, 2015: The new medicine to treat drug-resistant tuberculosis will be rolled out in four Indian cities and will be made available for free.
Council of Europe report upholds public health interests regarding the pharmaceutical industry (post)
UNAIDS has welcomed a report approved by the Parliamentary Assembly of the Council of Europe (PACE) on 29 September that recommends stronger regulation of the pharmaceutical sector to uphold public interest and prevent conflicts of interest.
IP clauses in FTAs should not go beyond TRIPS, generics manufacturers say (post)
Free trade agreements should include incentives for generic and biosimilar medicines, speakers said at a panel during the World Trade Organization Public Forum last week.
Eleventh hour TPP deal on biotech drugs still harms access to medications, may increase ire over TPP in Congress (post)
Oct. 5, 2015 -- The deal brokered today by the U.S. Trade Representative (USTR) and the Australian government on biotech drugs, which supposedly paved the way for an overall “deal in principle” for the Trans-Pacific Partnership (TPP), fell short of Big Pharma’s most extreme demands but will contribute to preventable suffering and death. The final deal as reported does not seem to adhere to the “May 10th 2007 Agreement” standard on access to affordable medicines and could complicate any eventual final TPP deal’s prospects in the U.S. Congress. In biologics and other areas, TPP rules would expand monopoly protections for the pharmaceutical industry at the expense of people’s access to affordable medicines. (The May 10th Agreement was brokered in 2007 between Democratic congressional leadership and the Bush administration to begin to reduce the negative consequences of U.S.-negotiated trade agreements, for health, the environment and labor.)
Statement by MSF on the conclusion of TPP negotiations in Atlanta (post)
"MSF expresses its dismay that TPP countries have agreed to United States government and multinational drug company demands that will raise the price of medicines for millions by unnecessarily extending monopolies and further delaying price-lowering generic competition. The big losers in the TPP are patients and treatment providers in developing countries. Although the text has improved over the initial demands, the TPP will still go down in history as the worst trade agreement for access to medicines in developing countries, which will be forced to change their laws to incorporate abusive intellectual property protections for pharmaceutical companies.
Response statement from Sandoz (post)
Due to stability issues impacting the intravenous tuberculosis treatment Rifampicin i.v., we have suspended production of this product. While the company recognizes that it is currently not able to supply the South African market and other markets worldwide with this specific formulation, Sandoz continues to supply Rifampicin in pill form to South African hospitals and healthcare providers. Patients with questions about their specific treatment should speak to a physician or healthcare professional.
At WTO, governments, health advocates see benefit from TRIPS; LDC waiver urged (post)
Access to medicines and innovations was the subject of a panel organised by civil society organisations at the World Trade Organization Public Forum last week. After 20 years of the WTO intellectual property agreement, panellists looked at the impact of the agreement on access to medicines, and in particular the use of its flexibilities. In addition, a delegate of India detailed the legal-political aspects of an upcoming WTO decision on disputes for harmful actions that do not technically violate any WTO rules.
Page 15 of 83 · Total posts: 0
←First 14 15 16 Last→